DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION

NIAID致力于结束艾滋病毒/艾滋病流行的必要研究，并寻找新的、更有效的基于免疫的疗法来补充抗逆转录病毒药物组合(CART)。艾滋病毒预防疫苗旨在解决未受感染者暴露的后果，即在感染发生时获得病毒或病毒载量减少。到目前为止，这种疫苗在感染对象中使用时还没有显示出治疗效果。因此，需要在感染者身上发挥作用的创新型治疗性生物制品。最近的研究还发现了许多抗艾滋病毒中和抗体，这些抗体的性质表明它们可能作为治疗剂有用。这些抗体具有有用和新颖的特性，包括效力、广泛的中和范围和其他抗体介导的效应器功能。进一步的研究表明，某些抗体可以被改造来提高结合特异性、效力或抗体效应器功能。人们还对基于治疗性骨髓移植的一次明显的艾滋病毒治愈和新生儿立即积极的抗逆转录病毒治疗的一次明显治愈的艾滋病毒根除或持续缓解的可能性产生了高度的兴趣。人们还对治疗性抗艾滋病毒疫苗、抗艾滋病毒抗体产品或其他基于免疫的抗艾滋病毒产品特别感兴趣，这些产品是作为艾滋病毒持续抑制/根除人类临床试验的一部分进行测试的治愈武器的一部分，以确定安全性和有效性。

NIAID is committed to research necessary to end the HIV/AIDS epidemic and in finding new and more effective immune based therapies that complement antiretroviral drug combinations (cART). HIV prevention vaccines are designed to address outcomes of exposure in uninfected persons, i.e. acquisition of virus or attenuation of viral load when infection occurs. Thus far, such vaccines have not demonstrated therapeutic efficacy when used in infected subjects. Thus the need exists for innovative therapeutic biological products that work in infected persons. Recent research has also identified numerous anti-HIV neutralizing antibodies with properties that suggest they may be useful as therapeutic agents. These antibodies have useful and novel properties including potency, broad ranges of neutralization, and other antibody-mediated effector functions. Additional research indicates certain antibodies may be engineered to improve binding specificity, potency, or antibody effector function. There is also heightened interest in the possibility of HIV eradication or sustained remission based on one apparent HIV cure due to therapeutic bone marrow transplant, and one apparent cure due to immediate and aggressive antiretroviral therapy in a newborn. There is also a specific interest in therapeutic anti-HIV vaccine, anti-HIV antibody products, or other immune-based anti-HIV products being part of a cure armamentarium to be tested as part of HIV sustained suppression/eradication human clinical trials to determine safety and efficacy.